|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
King T: HPV, cervical cancer, and you. J
Midwifery Womens Health. 53:263–264. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang JJ, Wang DD, Du CX and Wang Y: Long
noncoding RNA ANRIL promotes cervical cancer development by acting
as a sponge of miR-186. Oncol Res. May 22–2017.(Epub ahead of
print).
|
|
5
|
Yang M, Zhai X, Ge T, Yang C and Lou G:
MiR-181a-5p promotes proliferation and invasion, and inhibits
apoptosis of cervical cancer cells via regulating inositol
polyphosphate-5-phosphatase A (INPP5A). Oncol Res. 26:703–712.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang C, Zhou B, Liu M, Liu Y and Gao R:
miR-126-5p restoration promotes cell apoptosis in cervical cancer
by targeting Bcl2l2. Oncol Res. 25:463–470. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
John B, Enright AJ, Aravin A, Tuschl T,
Sander C and Marks DS: Human MicroRNA targets. PLoS Biol.
2:e3632004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhu K, He Y, Xia C, Yan J, Hou J, Kong D,
Yang Y and Zheng G: MicroRNA-15a inhibits proliferation and induces
apoptosis in CNE1 nasopharyngeal carcinoma cells. Oncol Res.
24:145–151. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou Y, Yang C, Wang K, Liu X and Liu Q:
MicroRNA-33b inhibits the proliferation and migration of
osteosarcoma cells via targeting hypoxia-inducible factor-1α. Oncol
Res. 25:397–405. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang S, Hui Y, Li X and Jia Q: WITHDRAWN:
Silencing of lncRNA-CCDC26 restrains the growth and migration of
glioma cells in vitro and in vivo via targeting miR-203. Oncol Res.
Jun 9–2017.(Epub ahead of print).
|
|
12
|
Luo C and Qiu J: MiR-181a inhibits
cervical cancer development via downregulating GRP78. Oncol Res.
25:1341–1348. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gao YL, Zhao ZS, Zhang MY, Han LJ, Dong YJ
and Xu B: Long noncoding RNA PVT1 facilitates cervical cancer
progression via negative regulating of miR-424. Oncol Res.
25:1391–1398. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang S, Liu F, Mao X, Huang J, Yang J,
Yin X, Wu L, Zheng L and Wang Q: Elevation of miR-27b by HPV16 E7
inhibits PPARγ expression and promotes proliferation and invasion
in cervical carcinoma cells. Int J Oncol. 47:1759–1766. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang HD, Jiang LH, Sun DW, Li J and Ji
ZL: The role of miR-130a in cancer. Breast Cancer. 24:521–527.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Feng Y, Zhou S, Li G, Hu C, Zou W, Zhang H
and Sun L: Nuclear factor-κB-dependent microRNA-130a upregulation
promotes cervical cancer cell growth by targeting phosphatase and
tensin homolog. Arch Biochem Biophys. 598:57–65. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yi X, Guo J, Sun S, Yang P, Wang J, Li Y,
Xie L, Cai J and Wang Z: EZH2-mediated epigenetic silencing of
TIMP2 promotes ovarian cancer migration and invasion. Sci Rep.
7:35682017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang Y, Li J, Xiang L, Han D, Shen X and
Wu X: 17β-Oestradiol activates proteolysis and increases invasion
through phosphatidylinositol 3-kinase pathway in human cervical
cancer cells. Eur J Obstet Gynecol Reprod Biol. 165:307–312. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kong Q, Wang W and Li P: Regulator role of
HPV E7 protein on miR-21 expression in cervical carcinoma cells and
its functional implication. Int J Clin Exp Pathol. 8:15808–15813.
2015.PubMed/NCBI
|
|
21
|
Shi M, Du L, Liu D, Qian L, Hu M, Yu M,
Yang Z, Zhao M, Chen C, Guo L, et al: Glucocorticoid regulation of
a novel HPV-E6-p53-miR-145 pathway modulates invasion and therapy
resistance of cervical cancer cells. J Pathol. 228:148–157. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu YK, Cheng N, Hu Y and Cen YZ: The role
of microRNAs in the pathogenesis of cervical cancer and its
relationship to HPV. Sheng Li Ke Xue Jin Zhan. 43:251–256. 2012.(In
Chinese). PubMed/NCBI
|
|
23
|
Zhang J, Li S, Yan Q, Chen X, Yang Y, Liu
X and Wan X: Interferon-β induced microRNA-129-5p down-regulates
HPV-18 E6 and E7 viral gene expression by targeting SP1 in cervical
cancer cells. PLoS One. 8:e813662013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang J, Wu H, Li P, Zhao Y, Liu M and
Tang H: NF-κB-modulated miR-130a targets TNF-α in cervical cancer
cells. J Transl Med. 12:1552014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Miao Y, Lu M, Yan Q, Li S and Feng Y:
Inhibition of proliferation, migration, and invasion by knockdown
of pyruvate kinase-M2 (PKM2) in ovarian cancer SKOV3 and OVCAR3
cells. Oncol Res. 24:463–475. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Braicu EI, Fotopoulou C, Chekerov R,
Richter R, Blohmer J, Kümmel S, Stamatian F, Yalcinkaya I, Mentze
M, Lichtenegger W and Sehouli J: Role of serum concentration of
VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer:
Results of a companion protocol of the randomized, NOGGO-AGO phase
III adjuvant trial of simultaneous cisplatin-based
radiochemotherapy vs.carboplatin and paclitaxel containing
sequential radiotherapy. Cytokine. 61:755–758. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pietruszewska W, Bojanowska-Poźniak K and
Kobos J: Matrix metalloproteinases MMP1, MMP2, MMP9 and their
tissue inhibitors TIMP1, TIMP2, TIMP3 in head and neck cancer: An
immunohistochemical study. Otolaryngol Pol. 70:32–43. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Braicu EI, Gasimli K, Richter R, Nassir M,
Kümmel S, Blohmer JU, Yalcinkaya I, Chekerov R, Ignat I, Ionescu A,
et al: Role of serum VEGFA, TIMP2, MMP2 and MMP9 in monitoring
response to adjuvant radiochemotherapy in patients with primary
cervical cancer-results of a companion protocol of the randomized
NOGGO-AGO phase III clinical trial. Anticancer Res. 34:385–391.
2014.PubMed/NCBI
|
|
29
|
Cardeal LB, Boccardo E, Termini L,
Rabachini T, Andreoli MA, di Loreto C, Longatto Filho A, Villa LL
and Maria-Engler SS: HPV16 oncoproteins induce MMPs/RECK-TIMP-2
imbalance in primary keratinocytes: Possible implications in
cervical carcinogenesis. PLoS One. 7:e335852012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao S, Yao D, Chen J, Ding N and Ren F:
MiR-20a promotes cervical cancer proliferation and metastasis in
vitro and in vivo. PLoS One. 10:e01209052015. View Article : Google Scholar : PubMed/NCBI
|
